IA
HARP

IFP Advisors’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

IFP Advisors’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3
Closed -$21 – 3609
2023
Q2 		$21 Hold
3
– – ﹤0.01% 3420
2023
Q1 		$392 Buy
+3
New +$25 ﹤0.01% 3213

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

IFP Advisors's HARP Position: Q3 2023 in Review

IFP Advisors sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q3 2023, closing a stake of 3 shares — an estimated $21 sold.

IFP Advisors first reported a position in HARP in Q1 2023 and held it in 2 quarters. The position peaked at $392 in Q1 2023. 32 funds tracked by Wall St. Rank hold HARP as of Q3 2023.

  • IFP Advisors reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • IFP Advisors sold 3 Harpoon Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $21.
  • IFP Advisors first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2023 and held it in 2 quarters.
  • IFP Advisors's Harpoon Therapeutics, Inc. Common Stock position peaked at $392 in Q1 2023.
  • 32 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q3 2023.

Based on IFP Advisors's 13F filing for Q3 2023, filed 12 Oct 2023.